glp-1 ibd Gut Hormones and Inflammatory Bowel Disease GLP-1 Receptor Agonists Reduce Colorectal

IQVIA data confirms combined Zepbound and Wegovy new patient starts increased 34% year-over-year in 2025

In the same line, many of the drugs that were given simultaneously with the GLP1RAs were administered in a single dose, again raising the question of whether the results can be inferred to the context of chronic use with multiple doses

The good news is that a low-fat, fiber-rich diet can help improve digestive function and naturally ease those side effects

Weight loss typically continues, with clinical trials showing that semaglutide 2.4 mg (Wegovy) produces average weight loss of approximately 15% by week 68, while tirzepatide (Zepbound) has demonstrated weight loss of approximately 15-21% across different doses by week 72